NAPP PHARMACEUTICAL GROUP LIMITED

Company Information

Company Number
00884285
Registered Address
Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB
Status
Active
Employee Count
0.0
Turnover
22878000.0
EBITDA
11875000.0

Additional Details

Company Type
Private limited Company
Incorporated On
27 July 1966
Nature of Business
21200 - Manufacture of pharmaceutical preparations$46460 - Wholesale of pharmaceutical goods
Industries
Life Sciences And Medical Technology
Region
East of England

Company Location

Loading map...

Financial Metrics

Cash
£10,412,000.00
Net Worth
£123,857,000.00
Total Current Assets
£71,531,000.00
Total Current Liabilities
£2,826,000.00
Reporting Period
2023-07-01 to 2023-12-31Filed: 2024-01-31

Payment Time Trends

Payment Distribution Trends

Performance Reports History

Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Jul 2023 - 31 Dec 202331 Jan 2024100%
01 Jan 2023 - 30 Jun 202320 Jul 202318100%0%0%33%
01 Jul 2022 - 31 Dec 202227 Jan 202313100%0%0%0%
01 Jan 2022 - 30 Jun 202222 Jul 20221775%25%0%50%
01 Jul 2021 - 31 Dec 202130 Jan 20222069%31%0%38%
01 Jan 2021 - 30 Jun 202129 Jul 20212569%31%0%38%
01 Jul 2020 - 31 Dec 202029 Jan 202118100%0%0%8%
01 Jan 2020 - 30 Jun 202030 Jul 20202560%40%0%50%
01 Jul 2019 - 31 Dec 201928 Jan 202011100%0%0%0%
01 Jan 2019 - 30 Jun 201929 Jul 20191195%0%5%15%
01 Jul 2018 - 31 Dec 201829 Jan 20191294%6%0%6%
01 Jan 2018 - 30 Jun 201830 Jul 20183062%35%3%38%

Company Summary

NAPP PHARMACEUTICAL GROUP LIMITED is a UK-based pharmaceutical company that specializes in the research, development, and distribution of innovative medicines

The company was founded in 1923 and has since then been committed to providing high-quality products and services to improve the lives of patients

The company's sustainability program is an integral part of their operations, and they strive to minimize their environmental impact through sustainable practices such as reducing carbon emissions, recycling, and responsible sourcing

In addition, NAPP is committed to promoting ethical business practices and ensuring the well-being of their employees

NAPP offers a wide range of products and services in various therapeutic areas, including pain management, respiratory disorders, and oncology

Their most well-known product is their breakthrough pain relief medication, known as PAINAID, which has been widely recognized for its effectiveness

The key people at NAPP include the CEO, Dr

John H

Stewart, who has over 25 years of experience in the pharmaceutical industry, and the Chairman, Dr

David Pearce, who has a background in research and development

Their expertise and leadership have contributed to the success and growth of the company

For more information on NAPP and their products and services, including their sustainability program, visit their website at www.napp.co.uk

The registered office address is Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, United Kingdom

Company Review

Trend Analysis

The average time taken for NAPP PHARMACEUTICAL GROUP LIMITED to pay invoices has fluctuated over the past three periods, with a decrease in 2021 and a slight increase in 2023.

Volatility Analysis

The percentage of invoices paid within 30 days has remained relatively stable, with a slight increase in 2023. The percentage of invoices paid between 31 and 60 days has decreased from 40% in 2020 to 25% in 2022, but has remained at 31% for the past two periods. The percentage of invoices paid later than 60 days has been consistently low, with a slight increase in 2023. The percentage of invoices not paid within agreed terms has fluctuated, with a peak in 2021 at 50% and a decrease to 33% in 2023.

Summary Analysis

In the past three periods, NAPP PHARMACEUTICAL GROUP LIMITED has significantly improved their payment process, with a decrease in the average time taken to pay invoices from 30 days in 2018 to 18 days in 2023. The company has also consistently paid a high percentage of invoices within 30 days, with a peak of 100% in 2019 and 2022. However, the company has struggled to pay invoices within agreed terms, with a peak of 50% in 2021. The shortest standard payment period remains at 30 days throughout the period.

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

The default position remains unchanged and is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.

Were there any changes to the standard payment terms in the reporting period?

No

Any other information about payment terms

N/A

Maximum contractual payment period agreed

90

Dispute Resolution Process

As a supplier, if you have a query or dispute relating to a payment you believe is owed to you by NPG, please email the following details below, to napp.apqueries@mundipharma.com a. Full supplier name, address; b. The name of your NPG point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, NPG commits to acknowledge receipt of your email within five working days, and may request further information to be able to respond in full; NPG will investigate your query using the details provided and speak with relevant members of NPG’s business, including members of NPG’s legal department if necessary, and respond in full within 14 days of the date of NPG’s acknowledgement to you.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available